title: Failure of the Nemo Trial: Bumetanide Is a Promising Agent to Treat Many Brain Disorders but Not Newborn Seizures.
abstract: The diuretic bumetanide failed to treat acute seizures due to hypoxic ischemic encephalopathy (HIE) in newborn babies and was associated with hearing loss (NEMO trial, Pressler et al., 2015). On the other hand, clinical and experimental observations suggest that the diuretic might provide novel therapy for many brain disorders including Autism Spectrum Disorders (ASD), schizophrenia, Rett syndrome, and Parkinson disease. Here, we discuss the differences between the pathophysiology of severe recurrent seizures in the neonates and neurological and psychiatric disorders stressing the uniqueness of severe seizures in newborn in comparison to other disorders.
authors.affiliation: INMED - Institut National de la Santé et de la Recherche Médicale U901, Aix-Marseille University Marseilles, France.
authors.forename: Yehezkel
authors.initials: Y
authors.lastname: Ben-Ari
authors.affiliation: Institut National de la Santé et de la Recherche Médicale, Centre d'Investigation Clinique 0004 Nantes, France.
authors.forename: Philippe
authors.initials: P
authors.lastname: Damier
authors.affiliation: Hôpital Le Cluzeau, CHU Limoges Limoges, France.
authors.forename: Eric
authors.initials: E
authors.lastname: Lemonnier
keywords: GABA; autism; bumetanide; clinical trials; epilepsy; parkinson disease